W
e live in the era of evidence-based medicine, so new interventions must meet criteria for both safety and effi cacy before they are adopted. However, we have inherited many practices adopted before the current standards were in place, and we have not always been rigorous in reevaluating traditional remedies. A conservative belief in established practice or the infl uence of vested interests may account for this lack of rigor in reappraisal. 1 Calcium and vitamin D supplements are possible examples of this phenomenon.
■ BONE METABOLISM IS TIGHTLY REGULATED
Bone is a connective tissue, its matrix composed principally of type 1 collagen, which provides tensile strength. Hydroxyapatite crystals, composed predominantly of calcium and phosphate, lie between the collagen fi bers and provide compressive strength. In a tightly regulated process, osteoblasts lay down the collagenous matrix, and osteoclasts remove it. Mineralization of newly formed bone proceeds if normal levels of extracellular calcium and phosphate are present, in the absence of inhibitors of mineralization.
High calcium intake does not drive bone formation
The endocrine system is critical in maintaining normocalcemia. A decrease in calcium intake results in increased parathyroid hormone secretion, resulting in increased renal tubular calcium reabsorption, increased bone turnover (both formation and resorption), and increased activation of vitamin D leading to increased intestinal absorption of calcium. High calcium intake reverses these changes. Thus, a normal serum calcium concentration can be maintained with calcium intake ranging from 200 to more than 2,000 mg/day, and rates of bone loss in postmenopausal women are unaffected by calcium intake (Figure 1 ). If calcium intake is very low, hypocalcemia and secondary hyperparathyroidism develop, 3 and bone mineralization may be impaired. However, levels of calcium intake in Africa and in East and Southeast Asia are typically less than 400 mg/day, 4 yet there is no evidence that these levels adversely affect skeletal health. In fact, fracture risk is lower in these regions than in North America, where calcium intake is several times greater.
Thus, some calcium intake is required to maintain circulating concentrations, but there is no mechanism by which high calcium intake can drive bone formation. Quite the opposite, in fact.
Vitamin D defi ciency has little relationship with diet
Vitamin D is a biologically inactive secosteroid activated by hydroxylation in the liver and kidney to function as the key regulator of intestinal calcium absorption. As with calcium, its defi ciency results in hypocalcemia and impaired bone mineralization.
Paradoxically, high levels of vitamin D stimulate bone resorption and inhibit bone mineralization in mice, 5 and large doses increase bone resorption markers acutely in clinical studies. 6 Thus, it is important to ensure an adequate vitamin D supply, but not an oversupply.
In the absence of supplements, most vitamin D is produced in the skin as a result of the action of ultraviolet light (from sunlight) on 7-dehydrocholesterol. Thus, vitamin D defi ciency occurs in those deprived of skin exposure to sunlight (eg, due to veiling, living at high latitude, staying permanently indoors), but it has little relationship with diet.
■ ARE CALCIUM SUPPLEMENTS EFFECTIVE?
Calcium supplements are certainly biologically active. They transiently increase serum calcium concentrations, suppress parathyroid hormone, and reduce bone resorption. 2 In the fi rst year of use, they increase bone density by about 1% compared with placebo. 7 However, longer use does not result in further bone density advantage over placebo, 7 suggesting that the response simply refl ects a decreased number of osteoclastic resorption sites and does not indicate a sustained change in bone balance.
A 1% difference in bone density would not be expected to reduce fracture risk, and a number of large, carefully conducted randomized controlled trials published over the last 15 years have failed to demonstrate anti fracture effi cacy for calcium. [8] [9] [10] [11] [12] As a result, the US Preventive Services Task Force recommends against the routine use of calcium supplements in community-dwelling adults. 13 In contrast, in a placebo-controlled trial published in 1992, Chapuy et al 14 found that elderly women residing in nursing homes who received calcium and vitamin D supplements had fewer fractures. At 18 months, by intention-to-treat analysis, nonvertebral fractures had occurred in 160 (12%) of 1,387 women in the supplement group compared with 215 (15%) of 1,403 women in the placebo group (P < .001). However, these women were severely vitamin D-defi cient (the mean serum 25-hydroxyvitamin D level at baseline in the placebo group was 13 ng/mL, normal range 15-50), to the extent that many must have had osteomalacia.
Thus, this study shows that calcium and vitamin D are effective in managing osteomalacia, but the subsequent trials [8] [9] [10] [11] [12] did not observe any benefi t in community-dwelling cohorts. Meta-analyses that pool the Chapuy study with community-based studies generally fi nd that calcium with vitamin D is benefi cial, but the heterogeneity of these populations means that such pooling is inappropriate. 15 It is sometimes stated that calcium and vitamin D should always be given with osteoporosis medications because the effi cacy of these drugs has only been demonstrated when coadministered with these supplements. This is incorrect. The addition of calcium to alendronate does not alter its effects on bone density, 16 and the antifracture effi cacy of both bisphosphonates 17 and estrogen 18, 19 has been demonstrated in the absence of supplementation with calcium or vitamin D. The evidence that bisphosphonates prevent fractures in the absence of calcium supplements has recently been strengthened by the results of a randomized controlled trial comparing zoledronate with placebo in women over age 65 with osteopenia. Calcium supplements often cause gastrointestinal symptoms, particularly constipation. They have been shown to double the risk of hospital admission due to abdominal symptoms. 21 In the absence of clear evidence of benefi t, these facts alone should militate against their routine use. Calcium supplements also cause hypercalcemia and hypercalciuria 22 and increase the risk of renal calculi (by 17% in the Women's Health Initiative 8 ).
. Over the last decade, evidence has emerged that calcium supplements may also increase the risk of myocardial infarction, and possibly stroke. This fi nding was not statistically signifi cant in any single study, but is consistently present in meta-analyses.
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Evidence from the Women's Health Initiative When studies of calcium with vitamin D are added to these meta-analyses, the results are less consistent. This is because such metaanalyses are dominated by the Women's Health Initiative (because of its large size, with 36,282 participants). There have been 2 different analyses of this trial with respect to cardiovascular events.
When the Women's Health Initiative as a whole was analyzed, there was no signifi cant effect of calcium plus vitamin D on vascular end points. However, there is a signifi cant interaction between body mass index and the effect of supplements, such that nonobese women demonstrated a 17% increase in myocardial infarction. 24 This study was unusual in that it included women already taking calcium and vitamin D supplements.
There was a signifi cant interaction between baseline use of supplements and the effects of the trial intervention on vascular events, justifying analyzing the supplement-naive individuals separately. In this group of 16,000 women, an increase in clinical myocardial infarction of 22% was found, similar to the fi ndings with calcium supplements alone. 25 Thus, there is consistent evidence that introducing a calcium supplement de novo increases the risk of myocardial infarction (Figure 2) . 16 needed to harm 178) and prevent only 3 fractures (number needed to treat 302).
■ ARE VITAMIN D SUPPLEMENTS EFFECTIVE?
Vitamin D is highly effective in treating osteomalacia, improving symptoms within days and increasing bone density by as much as 50% over 1 year. 32, 33 In contrast, randomized controlled trials of vitamin D supplements alone in people without osteomalacia have not shown increases in bone density or changes in fracture risk. [34] [35] [36] [37] In 2017, my colleagues and I published a trial showing that vitamin D supplementation increases bone density by 2% to 3% in the spine and femoral neck in participants with baseline 25-hydroxyvitamin D levels below 30-nmol/L (12 ng/mL), but those starting above this level showed no effect (Figure 3) . 38 And a reanalysis of an earlier study confi rmed this 30 nmol/L threshold for an effect of vitamin D on bone density. 39 The fi nding of a clear-cut threshold for vitamin D effects is predicted by the physiologic considerations set out above.
Belief that higher levels of 25-hydroxyvitamin D are better is based on observational data. However, correlation does not prove causation, and it is likely that causation is reversed here. Those with better health are likely to spend more time exercising outdoors, are less likely to be obese, and are less likely to have infl ammatory conditions; and as a result, they are more likely to have better vitamin D status. We should now be using trial-based defi nitions of vitamin D defi ciency as opposed to thresholds derived from disease associations in observational studies.
Vitamin D supplements have also been suggested to benefi t cardiovascular health and to reduce cancer risk, though current clinical trial data provide no support for these hypotheses. 36, 40 Other trials addressing these questions are ongoing.
■ ARE VITAMIN D SUPPLEMENTS SAFE?
The safety of vitamin D supplements has generally been assessed with respect to the incidence of hypercalcemia. On this basis, very high doses have been promoted. However, there is now evidence that doses of 4,000 IU/ day, 60,000 IU/month, and 500,000 IU/year increase the risk of falls and fractures. 41 
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The threshold for bone benefi ts discussed above (12 ng/mL) is easily exceeded with doses of vitamin D of 400 to 1,000 IU/day. At these levels, vitamin D supplements have no known adverse effects and can be widely endorsed for individuals at risk of defi ciency. Supplement doses greater than 2,000 IU/day should be used only in exceptional circumstances, and with appropriate monitoring.
■ LITTLE USE FOR CALCIUM AND VITAMIN D SUPPLEMENTS
Extensive clinical trials have failed to demonstrate meaningful benefi t from calcium supplements in the management of osteoporosis. Calcium supplements are often prescribed in patients who are receiving other treatments for osteoporosis, which may be justifi ed with interventions that have the potential to cause hypocalcemia, but their coadministration with bisphosphonates has been shown to be unnecessary. Calcium supplements commonly cause gastrointestinal symptoms that are sometimes severe and are likely to contribute to high levels of noncompliance with osteoporosis medications. They increase the risk of kidney stones, 8 and there is reasonable evidence to suggest an adverse effect on vascular risk as well. Our decision to prescribe calcium and vitamin D supplements should be based on evidence that is of the same quality as for any other intervention we prescribe. Current evidence suggests that there is little reason to prescribe calcium, and that vitamin D should be targeted at those at risk of 25-hydroxyvitamin D levels less than 12 ng/mL.
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